Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jefferies hikes Plus500 target price after results, buyback

(Sharecast News) - Markets gave a negative reaction to Plus500's annual results and share buyback announcement, but that didn't stop Jefferies from hiking its target price by nearly a fifth and reiterated a 'buy' recommendation. The online trading platform operator said it would return roughly $200m to shareholders via a share buyback and dividends, as it reported 2024 revenues had grown 6% to $768.3m, while underlying profits rose just 1% at $342.0m.

Nevertheless, shares were trading 4.2% lower at 2,745.08p by around midday on Tuesday, having dropped as much as 9% early on.

Jefferies said that it was tweaking its forecasts downwards after 2024 revenues beat estimates but profits missed slightly owing to higher costs. However, the broker said it believes there is upside risk to its projections for this year, "especially with the US business performing well".

"PLUS has remained on a c. 10x earnings multiple, despite giving the highest total shareholder returns of any stock over the period since its IPO in 2013. With revenues diversifying and an observable indicator of client activity in the US futures business, we think a higher multiple is justified," Jefferies said.

After accounting for an FX difference, the broker said a price-to-earnings multiple of 11 gives a 3,300p target price for the stock, up from 2,800p previously.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.